Core Cap Advisors, LLC Aerovate Therapeutics, Inc. Transaction History
Core Cap Advisors, LLC
- $2.12 Billion
- Q4 2024
A detailed history of Core Cap Advisors, LLC transactions in Aerovate Therapeutics, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 225 shares of AVTE stock, worth $551. This represents 0.0% of its overall portfolio holdings.
Number of Shares
225Holding current value
$551% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AVTE
# of Institutions
84Shares Held
31.3MCall Options Held
117KPut Options Held
245K-
Ra Capital Management, L.P. Boston, MA9.19MShares$22.5 Million0.39% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$9.21 Million0.81% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.49 Million0.97% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.41 Million0.79% of portfolio
-
Braidwell LP Stamford, CT1.44MShares$3.53 Million0.21% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $59.9M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...